References
1. Huang C., Wang Y., Li X., Ren L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. 2020. Vol. 395, N 10223. P. 497–506.
2. Johns Hopkins University of Medicine Coronavirus Resource Center. Data in Motion. 27.06.2021.
3. Wu Z., McGoogan J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention // JAMA. 2020. Vol. 323, N 13. P. 1239–1242. DOI: https://doi.org/10.1001/jama.2020.2648.
4. Yang X., Yu Y., Xu J., Shu H. et al Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // Lancet Respir. Med. 2020. Vol 8, N 5. P. 475–481. DOI: https://doi.org/10.1016/S2213-2600(20)30079-5
5. Horby P., Lim S., Emberson J.R. et al Dexamethasone in hospitalized patients with Covid-19 – Preliminary Report. The RECOVERY Collaborative Group // N. Engl. J. Med. 2021.Vol. 384, N 8. P. 693–704. DOI: https://doi.org/10.1056/NEJMoa2021436
6. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. 2020. Vol. 395, N 10229. P. 1054–1062. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
7. Carsana L., Sonzogni A., Nasr A. et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy:a two-centre descriptive study // Lancet Infect. Dis. 2020. Vol. 20, N 10. P. 1135–1140. DOI: https://doi.org/10.1016/S1473-3099(20)30434-5
8. Wong C.K., Lam C.W.K., Wu A.K.L. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome // Clin. Exp. Immunol. 2004. Vol. 136, N 1. P. 95–103. DOI: https://doi.org/10.1111/j.1365-2249.2004.02415.x
9. Baillie J.K., Digard P. Influenza – time to target the host? // N. Engl. J. Med. 2013. Vol. 369, N 2. P. 191–193. DOI: 10.1056/NEJMcibr1304414
10. Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19 // Science. 2020. Vol. 368, N 6490. P. 473–474. DOI: https://doi.org/10.1126/science.abb8925
11. Gupta S., Leaf D.E. Tocilizumab in COVID-19: some clarity amid controversy // Lancet. 2021.Vol. 397, N 10285. P. 1599–1601. DOI: https://doi.org/10.1016/S0140-6736(21)00712-1
12. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID‑19 based on an analysis of data of 150 patients from Wuhan, China // Intensive Care Med. 2020. Vol. 46, N 5. P. 846–848. DOI: https://doi.org/10.1007/s00134-020-05991-x
13. Временные методические рекомендации. “Профилактика и лечение новой коронавирусной инфекции (COVID-19).” Версия 11 (от 07.05.2021). Москва : Министерство здравоохранения Российской Федерации, 2021.
14. Rochwerg B., Siemieniuk R.A., Agoritsas T. еt al. Corticosteroids for COVID-19 Practice guideline // BMJ. 2020. Vol. 370. P. m3379. DOI: https://doi.org/10.1136/bmj.m3379
15. Tanaka T., Narazaki M., Kishimoto T., IL-6 in inflammation, immunity, and disease // Cold Spring Harb. Perspect Biol. 2014. Vol 6, N 10. P. 1–16. DOI: https://doi.org/10.1101/cshperspect.a016295
16. Kang S., Narazaki M., Metwally H., Kishimoto T. Historical overview of the interleukin-6 family cytokine // J. Exp. Med. 2020. Vol. 217, N 5. P. 1–10. DOI: https://doi.org/10.1084/jem.20190347
17. Murakami M., Kamimura D., Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines // Immunity 2019. Vol. 50, N 4. P. 812–823. DOI: https://doi.org/10.1016/j.immuni.2019.03.027
18. Samaee H., Mohsenzadegan M., Ala S. et al. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease // Int. Immunopharmacol. 2020. Vol. 89, PT A. 107018. DOI: https://doi.org/10.1016/j.intimp.2020.107018
19. Временные методические рекомендации. “Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)”: версия 9 (от 26.10.2020). Москва : Министерство здравоохранения Российской Федерации, 2020.
20. Kaplon H., Reichert J.M. Antibodies to watch in 2021 // Mabs. 2021. Vol. 13, N 1. 1860476. DOI: https://doi.org/10.1080/19420862.2020.1860476
21. Ghosn L., Chaimani A., Evrenoglou T. et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Meta-Analysis // Cochrane Database Syst. Rev. 2021. Vol. 3, CD013881. DOI: 10.1002/14651858.CD013881
22. Parr J.B. Time to reassess tocilizumab’s role in COVID-19 pneumonia // JAMA Intern. Med. 2021. Vol. 181, N 1. P 12–15. DOI: https://doi.org/10.1001/jamainternmed.2020.6557
23. Xu X., Han M., Li T. et al. Effective treatment of severe COVID-19 patients with tocilizumab // Nat. Acad. Sci. USA. 2020. Vol. 117, N 20. P. 10970–10975. DOI: https://doi.org/10.1073/pnas.2005615117
24. Luo P., Liu Y., Qiu L. et al Tocilizumab treatment in COVID-19: A single center experience // J. Med. Virol. 2020. Vol. 92, N 7. P. 814–818. DOI: https://doi.org/10.1002/jmv.25801
25. Guaraldi G., Meschiari M., Cozzi-Lepri A. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study // Lancet Rheumatol. 2020. Vol. 2, N 8. P. e474–e484. DOI: https://doi.org/10.1016/S2665-9913(20)30173-9
26. Somers E.C., Eschenauer G.A., Troost J.P. et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19 // Clin. Infect. Dis. 2020. Ciaa954. DOI: https://doi.org/10.1093/cid/ciaa954. Online ahead of print.
27. Biran N., Ip A., Ahn J. et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicenter observational study // Lancet Rheumatol. 2020. Vol. 2, N 10. P. e603–e612. DOI: https://doi.org/10.1016/S2665-9913(20)30277-0
28. Hermine O., Mariette X., Tharaux P-L. et al. for the CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial // JAMA Intern. Med. 2021. Vol. 181, N 1. P. 32–40. DOI: https://doi.org/10.1001/jamainternmed.2020.6820
29. Gupta S., Wang W., Hayek S.S. et al. Association between early treatment with tocilizumab and mortality among critically ill patients with covid-19 // JAMA Intern. Med. 2021. Vol. 181, N 1. P. 41–51. DOI: https://doi.org/10.1001/jamainternmed.2020.6252
30. REMAP-CAP Investigators; Gordon A. C., Mouncey P.R., Al-Beidh F. et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19 // N. Engl. J. Med. 2021. Vol. 384, N 16. P. 1491–1502. DOI: https://doi.org/10.1056/NEJMoa2100433
31. Alberici F., Delbarba E., Manenti C. et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. // Kidney Int. Rep. 2020. Vol. 5, N 5. P. 580–585. DOI.org/10.1016/j.ekir.2020.04.001
32. Trujillo H., Caravaca-Fontán F., Sevillano Á. et al. Tocilizumab use in kidney transplant patients with COVID-19 // Clin. Transplant. 2020. Vol. 34, N 11. E14072. DOI: https://doi.org/10.1111/ctr.14072
33. Pérez-Sáez M.J., Blasco M., Redondo-Pachón D. et al. Use of tocilizumab in kidney transplant recipients with COVID-19 // Am. J. Transplant. 2020. Vol. 20, N 11. P. 3182–3190. DOI: https://doi.org/10.1111/ajt.16192
34. Ким И.Г., Артюхина Л.Ю., Фролова Н.Ф. и др. SARS-CoV-2 инфекция у реципиентов почечного трансплантата // Нефрология и диализ. 2021. Т. 23, № 2. C. 174–184. DOI: https://doi.org/10.28996/2618-9801-2021-2-174-184
35. Фролова Н.Ф., Ким И.Г., Ушакова А.И. и др. COVID-19 у больных, получающих лечение программным гемодиализом // Инфекционные болезни: новости, мнения, обучение. 2021. Т. 10, № 1. С. 14–23. DOI: https://doi.org/10.33029/2305-3496-2021-10-1-14-23
36. Временные методические рекомендации. «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 8 (от 03.09.2020). Москва : Министерство здравоохранения Российской Федерации, 2020.
37. Levey A.S., Stevens L.A. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions // Am. J. Kidney Dis. 2010. Vol. 55, N 4. P. 622–627. DOI: https://doi.org/10.1053/j.ajkd.2010.02.337
38. Salvarani C., Dolci G., Massari M. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial // JAMA Intern. Med. 2021. Vol. 181, N 1. P. 24–31. DOI: https://doi.org/10.1001/jamainternmed.2020.6615
39. Stone J.H., Frigault M.J., Serling‑Boyd N.J. et al Efficacy of tocilizumab in patients hospitalized with Covid-19 // N. Engl. J. Med. 2020. Vol. 383, N 24. P. 2333–2344. DOI: https://doi.org/10.1056/NEJMoa2028836
40. Ng J.H., Bijol V., Sparks M.A. et al. Pathophysiology and pathology of acute kidney injury in patients with COVID-19 // Adv. Chronic Kidney Dis. 2020. Vol. 27, N 5. P. 365–376. DOI: https://doi.org/10.1053/j.ackd.2020.09.003